3 research outputs found
Heightened NLRP3 inflammasome activation is associated with aging and CMML diseases severity
Aging causes chronic low-grade inflammation known as inflamm-aging. It is a risk factor for
chronic myelomonocytic leukemia (CMML), a hematological malignancy that is most
prevalent in older people. Recent studies suggest a critical role for the NLRP3 inflammasome
in inflamm-aging. However, the mechanisms involved in NLRP3 activation in aging and its
involvement in CMML progression are not fully understood. Here, we report that aging
increases interleukin-1β production upon NLRP3 activation in human CD14+ monocytes.
Interestingly, we found that Toll-like receptor (TLR) 1/2 agonist Pam3Cysk4 directly activates
NLRP3 inflammasome without the requirement of second activation signal in monocytes from
older but not from younger healthy donors. Further, we observed a dichotomous response to
NLRP3 inflammasome activation in monocytes from CMML patients. Intriguingly, CMML
patients with heightened NLRP3 activation showed increased treatment dependency and
disease severity. Collectively, our results suggest that aging causes increased sensitivity to
NLRP3 inflammasome activation at cellular level, which may explain increased inflammation
and immune dysregulation in older individuals. Furthermore, NLRP3 inflammasome activation
was dysregulated in CMML and positively correlated with disease severity
Increased Inflammasome Activation Is Associated with Aging and Chronic Myelomonocytic Leukemia Disease Severity.
Aging causes chronic low-grade inflammation known as inflamm-aging. It is a risk factor for several chronic disorders, including chronic myelomonocytic leukemia (CMML), a hematological malignancy that is most prevalent in older people. Recent studies suggest a critical role for the NLRP3 (NOD-, LRR- and pyrin domain-containing protein 3) inflammasome in inflamm-aging. However, the mechanisms involved in NLRP3 activation in aging and its involvement in CMML progression are not fully understood. In this study, we report that aging increases IL-1β production upon NLRP3 activation in human CD14+ monocytes. Interestingly, we found that the TLR1/2 agonist Pam3CSK4 directly activates the NLRP3 inflammasome in monocytes from older but not from younger healthy donors. Furthermore, we observed a dichotomous response to NLRP3 inflammasome activation in monocytes from a small cohort of CMML patients, and some patients produced high levels of IL-1β and some patients produced low levels of IL-1β compared with older healthy donors. Intriguingly, CMML patients with heightened NLRP3 activation showed increased treatment dependency and disease severity. Collectively, our results suggest that aging causes increased sensitivity to NLRP3 inflammasome activation at a cellular level, which may explain increased inflammation and immune dysregulation in older individuals. Furthermore, NLRP3 inflammasome activation was dysregulated in a small cohort of CMML patients and was positively correlated with disease severity
Contribution of mutant HSC clones to immature and mature cells in MDS and CMML, and variations with AZA therapy.
Myelodysplastic Neoplasms (MDS) and Chronic Myelomonocytic Leukemia (CMML) are clonal disorders driven by progressively acquired somatic mutations in hematopoietic stem cells (HSCs). Hypomethylating agents (HMA) can modify the clinical course of MDS and CMML. Clinical improvement does not require eradication of mutated cells and may be related to improved differentiation capacity of mutated HSCs. However, in patients with established disease it is unclear whether; (a) HSCs with multiple mutations progress through differentiation with comparable frequency to their less mutated counterparts, or (b) improvements in peripheral blood counts following HMA therapy is driven by residual wild-type HSCs or by clones with particular combinations of mutations. To address these questions, we characterised the somatic mutations of individual stem, progenitor (common myeloid progenitor, granulocyte monocyte progenitor, megakaryocyte erythroid progenitor), and matched circulating (monocyte, neutrophil, naïve B) hematopoietic cells in MDS and CMML via high-throughput single-cell genotyping, followed by bulk analysis in immature and mature cells before and after AZA treatment. The mutational burden was similar throughout differentiation, with even the most mutated stem and progenitor clones maintained their capacity to differentiate to mature cell types in vivo. Increased contributions from productive mutant progenitors appear to underlie improved hematopoiesis in MDS following HMA therapy